Calliditas Therapeutics AB (publ) (CALTX.ST)
SEK 208.0
(0.87%)
SEK 208.0
(0.87%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 5.4 Million SEK | 101.04% |
| 2022 | -520.27 Million SEK | 29.91% |
| 2021 | -742.29 Million SEK | 25.14% |
| 2020 | -991.51 Million SEK | -32.65% |
| 2019 | -747.47 Million SEK | -15.68% |
| 2018 | -646.17 Million SEK | -1035.99% |
| 2017 | -56.88 Million SEK | -1087.71% |
| 2016 | 5.75 Million SEK | 122.89% |
| 2015 | -25.16 Million SEK | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 206.3 Million SEK | 3720.39% |
| 2024 Q2 | 210.99 Million SEK | 2.27% |
| 2023 FY | 5.4 Million SEK | 101.04% |
| 2023 Q3 | -16.72 Million SEK | 80.69% |
| 2023 Q2 | -86.61 Million SEK | 67.52% |
| 2023 Q1 | -266.7 Million SEK | 48.74% |
| 2023 Q4 | 5.4 Million SEK | 132.29% |
| 2022 Q2 | -388.77 Million SEK | 36.36% |
| 2022 FY | -520.27 Million SEK | 29.91% |
| 2022 Q1 | -610.91 Million SEK | 17.7% |
| 2022 Q3 | -268.84 Million SEK | 30.85% |
| 2022 Q4 | -520.27 Million SEK | -93.52% |
| 2021 Q1 | -866.02 Million SEK | 13.0% |
| 2021 FY | -742.29 Million SEK | 25.14% |
| 2021 Q4 | -742.29 Million SEK | 23.98% |
| 2021 Q3 | -976.39 Million SEK | -38.33% |
| 2021 Q2 | -705.82 Million SEK | 18.5% |
| 2020 Q1 | -726.23 Million SEK | 2.84% |
| 2020 Q2 | -1.45 Billion SEK | -100.75% |
| 2020 FY | -991.51 Million SEK | -32.65% |
| 2020 Q4 | -995.42 Million SEK | 28.69% |
| 2020 Q3 | -1.39 Billion SEK | 4.26% |
| 2019 Q1 | -596.85 Million SEK | 7.63% |
| 2019 Q4 | -747.47 Million SEK | 6.67% |
| 2019 Q3 | -800.86 Million SEK | -51.11% |
| 2019 Q2 | -529.99 Million SEK | 11.2% |
| 2019 FY | -747.47 Million SEK | -15.68% |
| 2018 FY | -646.17 Million SEK | -1035.99% |
| 2018 Q4 | -646.17 Million SEK | 5.79% |
| 2018 Q2 | -17.02 Million SEK | 67.93% |
| 2018 Q1 | -53.07 Million SEK | 6.69% |
| 2018 Q3 | -685.87 Million SEK | -3929.08% |
| 2017 Q1 | 24.24 Million SEK | 0.0% |
| 2017 Q4 | -56.88 Million SEK | 0.0% |
| 2017 FY | -56.88 Million SEK | -1087.71% |
| 2016 FY | 5.75 Million SEK | 122.89% |
| 2015 FY | -25.16 Million SEK | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -50.02 Million SEK | 110.795% |
| Ziccum AB (publ) | -2.13 Million SEK | 352.691% |
| Modus Therapeutics Holding AB (publ) | -19.06 Million SEK | 128.332% |
| BioArctic AB (publ) | -606.58 Million SEK | 100.89% |
| Sprint Bioscience AB (publ) | -49.93 Million SEK | 110.814% |
| Mendus AB (publ) | -96.29 Million SEK | 105.608% |
| Genovis AB (publ.) | -43.94 Million SEK | 112.289% |
| Intervacc AB (publ) | -88.16 Million SEK | 106.125% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 20.51 Million SEK | 73.671% |
| Active Biotech AB (publ) | -33.2 Million SEK | 116.265% |
| Magle Chemoswed Holding AB (publ) | 53.22 Million SEK | 89.854% |
| Bio-Works Technologies AB (publ) | -39.38 Million SEK | 113.712% |
| Aptahem AB (publ) | 2.9 Million SEK | -85.654% |
| Vicore Pharma Holding AB (publ) | -333.62 Million SEK | 101.619% |
| Kancera AB (publ) | -45.69 Million SEK | 111.818% |
| Infant Bacterial Therapeutics AB (publ) | -329.06 Million SEK | 101.641% |
| Fluicell AB (publ) | -2.76 Million SEK | 295.44% |
| Saniona AB (publ) | 40.44 Million SEK | 86.649% |
| Lipigon Pharmaceuticals AB (publ) | -31.92 Million SEK | 116.914% |
| Biovica International AB (publ) | -58.73 Million SEK | 109.194% |
| Spago Nanomedical AB (publ) | -45.21 Million SEK | 111.942% |
| AcouSort AB (publ) | -23.98 Million SEK | 122.513% |
| Xintela AB (publ) | -7.8 Million SEK | 169.151% |
| Abliva AB (publ) | -57.24 Million SEK | 109.434% |
| Egetis Therapeutics AB (publ) | -194.7 Million SEK | 102.773% |
| Karolinska Development AB (publ) | -82.2 Million SEK | 106.569% |
| OncoZenge AB (publ) | -12.62 Million SEK | 142.766% |
| Amniotics AB (publ) | -5.63 Million SEK | 195.881% |
| 2cureX AB (publ) | -13.4 Million SEK | 140.289% |
| CombiGene AB (publ) | -101.44 Million SEK | 105.323% |
| Asarina Pharma AB (publ) | -2.16 Million SEK | 349.884% |
| Camurus AB (publ) | -1.16 Billion SEK | 100.463% |
| Corline Biomedical AB | -17.01 Million SEK | 131.742% |
| IRLAB Therapeutics AB (publ) | -83.74 Million SEK | 106.448% |
| Isofol Medical AB (publ) | -138.14 Million SEK | 103.909% |
| I-Tech AB | -83.26 Million SEK | 106.486% |
| Hansa Biopharma AB (publ) | 134.7 Million SEK | 95.991% |
| Cyxone AB (publ) | -16.67 Million SEK | 132.394% |
| ExpreS2ion Biotech Holding AB (publ) | -55.88 Million SEK | 109.663% |
| Biosergen AB | -1.88 Million SEK | 386.776% |
| Cantargia AB (publ) | -139.74 Million SEK | 103.864% |
| NextCell Pharma AB | -46.79 Million SEK | 111.541% |
| Xspray Pharma AB (publ) | -129.49 Million SEK | 104.17% |
| Elicera Therapeutics AB (publ) | -29.38 Million SEK | 118.378% |
| Nanologica AB (publ) | -9.38 Million SEK | 157.52% |
| SynAct Pharma AB | -61.75 Million SEK | 108.744% |
| Annexin Pharmaceuticals AB (publ) | -21.41 Million SEK | 125.216% |
| Stayble Therapeutics AB (publ) | -13.22 Million SEK | 140.819% |
| LIDDS AB (publ) | -13.51 Million SEK | 139.964% |
| Lipum AB (publ) | -8.46 Million SEK | 163.792% |
| BioInvent International AB (publ) | -236.3 Million SEK | 102.285% |
| Alzinova AB (publ) | -21.22 Million SEK | 125.44% |
| Oncopeptides AB (publ) | -66.92 Million SEK | 108.069% |
| Pila Pharma AB (publ) | -5.18 Million SEK | 204.229% |
| Guard Therapeutics International AB (publ) | -83.74 Million SEK | 106.448% |
| Scandinavian ChemoTech AB (publ) | -923 Thousand SEK | 685.049% |
| Simris Alg AB (publ) | 85.07 Million SEK | 93.653% |
| Diamyd Medical AB (publ) | -82.08 Million SEK | 106.578% |
| Xbrane Biopharma AB (publ) | 166.07 Million SEK | 96.748% |
| Ascelia Pharma AB (publ) | -20.79 Million SEK | 125.97% |
| Diagonal Bio AB (publ) | -2.97 Million SEK | 281.696% |